| Identification | Back Directory | [Name]
(S)-2-(4-(2-chlorophenoxy)-2-oxo-2,5-dihydro-1H-pyrrol-1-yl)-N-(1-((R)-2,3-dihydroxypropyl)-1H-pyrazol-3-yl)-4-MethylpentanaMide | [CAS]
1191995-00-2 | [Synonyms]
RO-5305552
DORZAGLIATIN;1191995-00-2;DORZAGLIATIN; SINOGLIATIN ;HMS5552; RO5305552
(S)-2-(4-(2-chlorophenoxy)-2-oxo-2,5-dihydro-1H-pyrrol-1-yl)-N-(1-((R)-2,3-dihyd
(S)-2-(4-(2-chlorophenoxy)-2-oxo-2,5-dihydro-1H-pyrrol-1-yl)-N-(1-((R)-2,3-dihydroxypropyl)-1H-pyrazol-3-yl)-4-MethylpentanaMide
(S)-2-[4-(2-chloro-phenoxy)-2-oxo-2,5-dihydro-pyrrol-1-yl]-4-methyl-pentanoic acid [1-((R)-2,3-dihydroxy-propyl)-1H-pyrazol-3-yl]-amide
1H-Pyrrole-1-acetamide, 4-(2-chlorophenoxy)-N-[1-[(2R)-2,3-dihydroxypropyl]-1H-pyrazol-3-yl]-2,5-dihydro-α-(2-methylpropyl)-2-oxo-, (αS)- | [Molecular Formula]
C22H27ClN4O5 | [MDL Number]
MFCD22376579 | [MOL File]
1191995-00-2.mol | [Molecular Weight]
462.93 |
| Chemical Properties | Back Directory | [Boiling point ]
761.7±60.0 °C(Predicted) | [density ]
1.38±0.1 g/cm3(Predicted) | [solubility ]
DMSO:108.5(Max Conc. mg/mL);234.38(Max Conc. mM)
Ethanol:92.0(Max Conc. mg/mL);198.73(Max Conc. mM) | [form ]
Solid | [pka]
12.84±0.70(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Dorzagliatin (HMS5552), a dual-acting glucokinase (GK) activator, improves glycaemic control and pancreatic β-cell function in type 2 diabetes[1]. | [in vivo]
Dorzagliatin (low-dose 10?mg/kg, and high-dose 30?mg/kg; administered intragastrically; daily 8:00 AM for one month) exerts a glucose-lowering effect on the glucose levels in diabetic rats[2. | Animal Model: | Male Sprague-Dawley (SD) rats (aged approximately 6–8 weeks and weighing 200-230?g)[2 | | Dosage: | Low-dose (10?mg/kg), and high-dose (30?mg/kg) | | Administration: | Administered intragastrically (i.g.); daily (8:00 AM) for one month | | Result: | Exerted a glucose-lowering effect on the glucose levels. |
| [References]
[1] Zhu XX, et al. Dorzagliatin (HMS5552), a novel dual-acting glucokinase activator, improves glycaemic control and pancreatic β-cell function in patients with type 2 diabetes: A 28-day treatment study using biomarker-guided patient selection. Diabetes Obes DOI:10.1111/dom.13338
[2] Wang P, et al. Effects of a Novel Glucokinase Activator, HMS5552, on Glucose Metabolism in a Rat Model of Type 2 Diabetes Mellitus. J Diabetes Res. 2017;2017:5812607. DOI:10.1155/2017/5812607 |
|
|